Letters

Drivers who take insulin must tell Driver and Vehicle Licensing Agency

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7242.1148/b (Published 22 April 2000) Cite this as: BMJ 2000;320:1148
  1. N Essex, member,
  2. P J Watkins, chairman,
  3. J Durston, senior medical adviser
  4. On behalf of the Honorary Medical Advisory Panel on Driving and Diabetes Mellitus
  1. Driver and Vehicle Licensing Agency, Drivers Medical Unit, Swansea SA6 7JL

    EDITOR—The DIGAMI study (diabetes mellitus insulin glucose infusion in acute myocardial infarction) suggested that insulin treatment at the time of myocardial infarction offered some improvement in mortality, particularly in patients not previously treated with insulin.1 As a result of this study insulin has been started acutely after myocardial infarction in many such patients.

    Any patient who starts taking insulin is legally obliged to inform the Driver and Vehicle Licensing Agency, and the standard advice is that he or she should not drive for at least a month. As many patients are advised not to drive for at least this period after infarction there may be no immediate concern. Many of these patients are, however, treated with insulin for several months, and some of them seem to be unaware of their obligations regarding driving.

    We would urge that all patients who are advised to start taking insulin are referred quickly for expert diabetological advice; in particular, they should be advised about their legal obligation as regards informing the Driver and Vehicle Licensing Agency. There is a risk of hypoglycaemia, and this risk would be diminished by early referral for expert advice on stabilisation and adjustment of insulin doses.

    References

    1. 1.
    View Abstract

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe